Literature DB >> 22948343

[Antiretroviral treatment of HIV-1 infection].

H-J Stellbrink1.   

Abstract

Antiretroviral treatment of HIV-1 infection requires a combination of compounds from different drug classes. It aims at life-long virus suppression, resulting in prevention of disease progression and improvement of life expectancy as well as quality of life. Efficacy, resistance, side effects, drug interactions, and patient preferences have to be considered along with factors improving long-term high-level adherence. Treatment indication is primarily based on clinical symptoms and CD4(+) T-cell count. In view of the perspective of treatment over decades, the complexity of therapeutic considerations increases and requires a high level of continuing medical education.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22948343     DOI: 10.1007/s00108-011-2974-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  14 in total

1.  Late presentation of HIV infection: a consensus definition.

Authors:  A Antinori; T Coenen; D Costagiola; N Dedes; M Ellefson; J Gatell; E Girardi; M Johnson; O Kirk; J Lundgren; A Mocroft; A D'Arminio Monforte; A Phillips; D Raben; J K Rockstroh; C Sabin; A Sönnerborg; F De Wolf
Journal:  HIV Med       Date:  2011-01       Impact factor: 3.180

2.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

3.  Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals.

Authors:  Ard I van Sighem; Luuk A J Gras; Peter Reiss; Kees Brinkman; Frank de Wolf
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

4.  Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

Authors:  Melanie A Thompson; Judith A Aberg; Pedro Cahn; Julio S G Montaner; Giuliano Rizzardini; Amalio Telenti; José M Gatell; Huldrych F Günthard; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; Peter Reiss; Douglas D Richman; Paul A Volberding; Patrick Yeni; Robert T Schooley
Journal:  JAMA       Date:  2010-07-21       Impact factor: 56.272

5.  Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.

Authors:  Ravindra Gupta; Andrew Hill; Anthony W Sawyer; Deenan Pillay
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

6.  Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.

Authors:  David R Bangsberg; Edward P Acosta; Reena Gupta; David Guzman; Elise D Riley; P Richard Harrigan; Neil Parkin; Steven G Deeks
Journal:  AIDS       Date:  2006-01-09       Impact factor: 4.177

7.  Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

Authors:  Luigia Elzi; Catia Marzolini; Hansjakob Furrer; Bruno Ledergerber; Matthias Cavassini; Bernard Hirschel; Pietro Vernazza; Enos Bernasconi; Rainer Weber; Manuel Battegay
Journal:  Arch Intern Med       Date:  2010-01-11

8.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.

Authors: 
Journal:  Lancet       Date:  2008-07-26       Impact factor: 79.321

9.  No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.

Authors:  Marlous L Grijsen; Radjin Steingrover; Ferdinand W N M Wit; Suzanne Jurriaans; Annelies Verbon; Kees Brinkman; Marchina E van der Ende; Robin Soetekouw; Frank de Wolf; Joep M A Lange; Hanneke Schuitemaker; Jan M Prins
Journal:  PLoS Med       Date:  2012-03-27       Impact factor: 11.069

10.  Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.

Authors:  Andrew Zolopa; Janet Andersen; William Powderly; Alejandro Sanchez; Ian Sanne; Carol Suckow; Evelyn Hogg; Lauren Komarow
Journal:  PLoS One       Date:  2009-05-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.